Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 5, 2018

Primary Completion Date

March 3, 2022

Study Completion Date

March 3, 2022

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG

Quizartinib

Quizartinib is provided as 20 mg tablets for oral administration

Trial Locations (1)

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin